News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
352,036 Results
Type
Article (21593)
Company Profile (137)
Press Release (330298)
Multimedia
Podcasts (131)
Webinars (20)
Section
Business (106165)
Career Advice (902)
Deals (18770)
Drug Delivery (127)
Drug Development (51227)
Employer Resources (80)
FDA (7923)
Job Trends (7866)
News (187481)
Policy (17501)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (752)
Accelerated approval (35)
ADA (26)
Adcomms (25)
Allergies (118)
Alliances (27974)
ALS (120)
Alzheimer's disease (880)
Antibody-drug conjugate (ADC) (318)
Approvals (8229)
Artificial intelligence (387)
ASCO (174)
Autoimmune disease (180)
Automation (26)
Bankruptcy (181)
Best Places to Work (5554)
BIO (30)
BIOSECURE Act (14)
Biosimilars (207)
Biotechnology (59)
Bladder cancer (91)
Brain cancer (45)
Breast cancer (331)
Cancer (2986)
Cardiovascular disease (307)
Career advice (758)
Career pathing (30)
CAR-T (139)
CDC (21)
Cell therapy (371)
Cervical cancer (22)
Clinical research (45980)
Collaboration (1309)
Commercialization (1)
Company closure (2)
Compensation (476)
Complete response letters (71)
COVID-19 (1177)
CRISPR (63)
C-suite (788)
Cystic fibrosis (95)
Data (4554)
Decentralized trials (3)
Denatured (30)
Depression (102)
Dermatology (53)
Diabetes (326)
Diagnostics (1976)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (250)
Drug pricing (220)
Drug shortages (36)
Duchenne muscular dystrophy (177)
Earnings (41961)
Editorial (55)
Employer branding (10)
Employer resources (79)
Events (52391)
Executive appointments (719)
FDA (9941)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (7)
Frontotemporal dementia (10)
Funding (853)
Gene editing (113)
Generative AI (45)
Gene therapy (332)
GLP-1 (933)
Government (2073)
Grass and pollen (4)
Guidances (218)
Healthcare (6015)
Hematology (92)
HIV (44)
Huntington's disease (33)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (83)
Immunology and inflammation (218)
Immuno-oncology (59)
Indications (143)
Infectious disease (1367)
Inflammatory bowel disease (149)
Inflation Reduction Act (12)
Influenza (61)
Intellectual property (169)
Interviews (123)
IPO (7454)
IRA (54)
Job creations (2449)
Job search strategy (657)
JPM (55)
Kidney cancer (14)
Labor market (82)
Layoffs (363)
Leadership (35)
Legal (4159)
Liver cancer (41)
Longevity (15)
Lung cancer (420)
Lymphoma (262)
Machine learning (25)
Management (31)
Manufacturing (736)
Marketing (2)
MASH (139)
Medical affairs (1)
Medical device (2020)
Medtech (2040)
Mergers & acquisitions (11951)
Metabolic disorders (1137)
mRNA (111)
Multiple sclerosis (127)
NASH (21)
Neurodegenerative disease (224)
Neuropsychiatric disorders (92)
Neuroscience (1841)
Neurotech (1)
NextGen: Class of 2026 (2368)
Non-profit (924)
Now hiring (60)
Obesity (654)
Opinion (249)
Ovarian cancer (100)
Pain (188)
Pancreatic cancer (136)
Parkinson's disease (223)
Partnered (19)
Patents (354)
Patient recruitment (395)
Peanut (22)
People (35095)
Pharmaceutical (71)
Pharmacy benefit managers (38)
Phase 1 (14521)
Phase 2 (19402)
Phase 3 (15561)
Pipeline (5340)
Policy (265)
Postmarket research (1624)
Preclinical (5079)
Press Release (29)
Prostate cancer (173)
Psychedelics (38)
Radiopharmaceuticals (220)
Rare diseases (725)
Real estate (3215)
Recruiting (34)
Regulatory (14438)
Reports (27)
Research institute (848)
Resumes & cover letters (142)
Rett syndrome (13)
RNA editing (17)
RSV (51)
Schizophrenia (148)
Series A (167)
Series B (105)
Service/supplier (7)
Sickle cell disease (79)
Special edition (24)
Spinal muscular atrophy (126)
Sponsored (20)
Startups (2059)
State (2)
Stomach cancer (13)
Supply chain (95)
Tariffs (97)
The Weekly (98)
Vaccines (473)
Venture capital (92)
Weight loss (465)
Women's health (68)
Worklife (10)
Date
Today (41)
Last 7 days (224)
Last 30 days (1298)
Last 365 days (15235)
2026 (7832)
2025 (15471)
2024 (17663)
2023 (19636)
2022 (25866)
2021 (26638)
2020 (24870)
2019 (20055)
2018 (15587)
2017 (17252)
2016 (16203)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (420)
Alabama (48)
Alaska (1)
Arizona (105)
Arkansas (9)
Asia (26431)
Australia (3413)
California (5962)
Canada (2197)
China (1019)
Colorado (246)
Connecticut (247)
Delaware (243)
Europe (54594)
Florida (1052)
Georgia (118)
Hawaii (2)
Idaho (20)
Illinois (580)
India (75)
Indiana (368)
Iowa (5)
Japan (451)
Kansas (91)
Kentucky (34)
Louisiana (11)
Maine (4)
Maryland (717)
Massachusetts (4765)
Michigan (77)
Minnesota (302)
Mississippi (3)
Missouri (49)
Montana (13)
Nebraska (15)
Nevada (41)
New Hampshire (11)
New Jersey (2297)
New Mexico (21)
New York (1634)
North Carolina (957)
North Dakota (2)
Northern California (2885)
Ohio (162)
Oklahoma (8)
Oregon (23)
Pennsylvania (1302)
Puerto Rico (28)
Rhode Island (29)
South America (617)
South Carolina (13)
South Dakota (1)
Southern California (2552)
Tennessee (82)
Texas (822)
United States (22451)
Utah (109)
Vermont (1)
Virginia (232)
Washington D.C. (60)
Washington State (473)
West Virginia (1)
Wisconsin (64)
Wyoming (1)
352,036 Results for "recce pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA Pharma has put out its analysis. Skyrocketing sales and multiple FDA approvals helped the company shoot to the top.
May 26, 2026
·
2 min read
·
Tristan Manalac
China
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines
Recent deals from Pfizer and Bristol Myers Squibb hint at Big Pharma’s more collaborative approach to partnering with Chinese companies.
June 2, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.
June 10, 2026
·
1 min read
·
Annalee Armstrong
Manufacturing
Pharma manufacturing projected to create 19,000 jobs through 2034
The forecast makes pharma one of the fastest-growing manufacturing industries in the U.S.
June 3, 2026
·
2 min read
·
Nick Paul Taylor
C-suite
Lilly, J&J CEOs top pharma’s highest paid list—again
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.
May 13, 2026
·
5 min read
·
Annalee Armstrong
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.
May 20, 2026
·
1 min read
·
Jef Akst
Government
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following the second rejection of Replimune’s advanced melanoma drug.
April 17, 2026
·
2 min read
·
Tristan Manalac
Earnings
On steadier ground, pharma heads into Q1 earnings with deals top of mind
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trump’s new tariffs.
April 14, 2026
·
5 min read
·
Annalee Armstrong
Manufacturing
How US pharma manufacturing pay stacks up to other jobs in the industry
Anticipated to be one of fastest-growing jobs in manufacturing, pharmaceutical jobs offer a salary 32% higher than the average U.S. manufacturing role.
June 23, 2026
·
1 min read
·
Gabrielle Masson
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with Trump’s Most Favored Nation policy, patients will suffer.
April 2, 2026
·
3 min read
·
Annalee Armstrong
1 of 35,204
Next
